{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:04:34Z","timestamp":1769634274749,"version":"3.49.0"},"reference-count":34,"publisher":"Pan African Medical Journal","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PAMJ"],"abstract":"<jats:p>Introduction: despite the success of antiretroviral therapy (ART), the emergence of HIV drug resistance (HIVDR) remains a major threat in sub-Saharan Africa, where therapeutic options remain limited. With the goal of supporting ART response, we sought to monitor viral load (VL) response and acquired HIVDR emergence among patients initiating ART in the Cameroonian setting.\n\n \n\nMethods: a facility-based cohort study was conducted from March 2016 to May 2021 in urban (Yaound\u00e9) and rural (Obala) settings in the centre region of Cameroon. Included were recently diagnosed HIV individuals initiating ART at the level of the health facilities. VL was measured at three different time points. For those with unsuppressed viremia (&gt;1000 copies\/mL), genotyping for HIVDR was performed in the protease, reverse-transcriptase, and integrase gene regions, and interpreted using HIVdb.v9.1. Data were analyzed with p&lt;0.05 considered significant. Time-to-event analysis (Kaplan-Meier and Cox regression) was used to identify determinants of virological failure.\n\n \n\nResults: overall, 87 newly diagnosed participants (50.6% from urban and 49.4% from rural) were enrolled. Median (interquartile range, IQR) age was 42 (34.0-50.5) years, sex ratio (F\/M) was 3\/2, and all participants initiated treatment with non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART regimen. At initiation, median VL was 34,000 (13,963-122,000) copies\/mL; at T1 (~3 years after initiation), median VL dropped to 9,800 (4,700-30,500) copies\/mL, and 17.2% (15\/87) switched to protease inhibitor-based ART. At the end of the study (T2), 58.6% (51\/87) had achieved undetectable VL (&lt;40copies\/mL), 3.4% had VL between 40-999 copies\/mL, and 37.9% VL &gt;1000 copies\/mL. The proportion with virological failure was 9.1% (4\/44) in the urban setting versus 67.4% (29\/43) in the rural setting. Time-to-event analysis revealed that patients in the rural setting had a 4.6-fold higher risk of virological failure (hazard ratio (HR) = 4.60, 95% CI: 2.29-9.27). Among those with unsuppressed VL, overall rate of HIVDR was 62.5% (20\/32), driven by the mutations: M184V (31.25%) for NRTI, K103N (18.75%) for NNRTI and M46I (9.30%) for PI\/r, and 0% major resistance mutations to integrase strand transfer inhibitors (INSTI), without any significant disparity between urban and rural.\n\n \n\nConclusion: viral load monitoring reveals poor ART response in rural settings, which prompts the need for improving access to ART. Among those with unsuppressed VL, the burden and patterns of HIVDR are similar in both settings, likely due to the wide use of NNRTI-based ART. Viral susceptibility to INSTIs supports a possible switch to dolutegravir-based ART for optimal response.<\/jats:p>","DOI":"10.11604\/pamj.2025.52.122.46773","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T09:16:00Z","timestamp":1769591760000},"source":"Crossref","is-referenced-by-count":0,"title":["Monitoring of virological response and acquired HIV-1 drug resistance among patients initiating antiretroviral therapy in the centre region of Cameroon"],"prefix":"10.11604","author":[{"given":"Bello","family":"Djoda","sequence":"first","affiliation":[{"name":"Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Fru-Cho","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick Achiangia","family":"Njukeng","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezechiel Ngoufack","family":"Jagni Semengue","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management (CIRCB), Yaound\u00e9, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3724-3527","authenticated-orcid":false,"given":"Patrick Valere","family":"Tsouh Fokou","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Science, University of Bamenda, Bambili, Bamenda, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evariste","family":"Molimbou","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management (CIRCB), Yaound\u00e9, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi-Karell","family":"Etame","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management (CIRCB), Yaound\u00e9, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigue","family":"Kamga","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bauer","family":"Wilhelm","sequence":"additional","affiliation":[{"name":"BIOMEX GmbH, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"D\u00e4chert","sequence":"additional","affiliation":[{"name":"Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, LMU Munich, Germany, German Center for Infection Research (DZIF), Partner Site Munich, Munich, Bavaria, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain Nantchouang","family":"Megaptche","sequence":"additional","affiliation":[{"name":"BIOMEX GmbH, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Muenchhoff","sequence":"additional","affiliation":[{"name":"Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, LMU Munich, Germany, German Center for Infection Research (DZIF), Partner Site Munich, Munich, Bavaria, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abel","family":"Wade","sequence":"additional","affiliation":[{"name":"National Veterinary Laboratory, Garoua, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie Van","family":"Cleaf","sequence":"additional","affiliation":[{"name":"BIOMEX GmbH, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Eberle","sequence":"additional","affiliation":[{"name":"Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, LMU Munich, Germany, German Center for Infection Research (DZIF), Partner Site Munich, Munich, Bavaria, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Fokounang","sequence":"additional","affiliation":[{"name":"Department of Pharmacotoxicology and Pharmacokinetics, Faculty of Medicine and Biomedical Sciences, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Fokam","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Buea, Buea, Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver Till","family":"Keppler","sequence":"additional","affiliation":[{"name":"Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, LMU Munich, Germany, German Center for Infection Research (DZIF), Partner Site Munich, Munich, Bavaria, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Bosnjak","sequence":"additional","affiliation":[{"name":"BIOMEX GmbH, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4870","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"ref0","unstructured":"The Global HIV and AIDS Epidemic. Accessed 4th February 2025."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Fokam J, Nangmo A, Wandum C, Takou D, Santoro MM, Nlend AN et al. Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon. AIDS Res Ther. 2020 May 12;17(1):14. PubMed | Google Scholar","DOI":"10.1186\/s12981-020-00270-7"},{"key":"ref2","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS). Fast-track, ending the AIDS epidemic by 2030. 2014."},{"key":"ref3","unstructured":"World Health Organization. HIV drug resistance report 2019. 2019. Accessed 4th February 2025."},{"key":"ref4","unstructured":"World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2016. PubMed | Google Scholar"},{"key":"ref5","unstructured":"World Health Organization. Global Action Plan on HIV drug resistance 2017-2021. 2017. Google Scholar"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Broyles LN, Luo R, Boeras D, Vojnov L. The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review. Lancet. 2023 Aug 5;402(10400):464-471. PubMed | Google Scholar","DOI":"10.1016\/S0140-6736(23)00877-2"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Fokam J, Chenwi CA, Tala V, Takou D, Santoro MM, Teto G et al. Pre-Treatment HIV Drug Resistance and Genetic Diversity in Cameroon: Implications for First-Line Regimens. Viruses. 2023 Jun 28;15(7):1458. PubMed | Google Scholar","DOI":"10.3390\/v15071458"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Gregson J, Tang M, Ndembi N, Hamers RL, Marconi VC, Brooks K et al. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016 May;16(5):565-575. PubMed | Google Scholar","DOI":"10.1016\/S1473-3099(15)00536-8"},{"key":"ref9","unstructured":"World Health Organization. Surveillance of HIV Drug Resistance in Adults Initiating Antiretroviral Therapy (Pre-Treatment HIV Drug Resistance). 2014."},{"key":"ref10","unstructured":"World Health Organization. HIV drug resistance report 2017. 2017."},{"key":"ref11","unstructured":"MINSATE. Politique nationale des laboratoires du Cameroun. 2022."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Cheng Z, Lin P, Cheng N. HBV\/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases. Front Med (Lausanne). 2021 Oct 4;8:713981. PubMed | Google Scholar","DOI":"10.3389\/fmed.2021.713981"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Teame G, Gebreyesus A, Tsegay E, Gebretsadik M, Adane K. Hepatitis B and C viral coinfections and their association with HIV viral load suppression among HIV-1 infected patients on ART at Mekelle hospital, northern Ethiopia. AIDS Res Ther. 2022 Dec 1;19(1):57. PubMed | Google Scholar","DOI":"10.1186\/s12981-022-00479-8"},{"key":"ref14","unstructured":"Stanford University. HIV Drug Resistance Database. 2024. Accessed 4th February 2025."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Fokam J, Bellocchi MC, Armenia D, Nanfack AJ, Carioti L, Continenza F et al. Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. Medicine (Baltimore). 2018 Mar;97(13):e0176. PubMed | Google Scholar","DOI":"10.1097\/MD.0000000000010176"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Inzaule SC, Hamers RL, Doherty M, Shafer RW, Bertagnolio S, Rinke de Wit TF. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens. Lancet Infect Dis. 2019 Jul;19(7):e246-e252. PubMed | Google Scholar","DOI":"10.1016\/S1473-3099(18)30710-2"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018 Jul;5(7):e347-e356. PubMed | Google Scholar","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Dow DE, Bartlett JA. Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV. Infect Dis Ther. 2014 Dec;3(2):83-102. PubMed | Google Scholar","DOI":"10.1007\/s40121-014-0029-7"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Han YS, Mespl\u00e8de T, Wainberg MA. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors. Infect Genet Evol. 2016 Dec:46:286-291. PubMed | Google Scholar","DOI":"10.1016\/j.meegid.2016.06.047"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Inzaule SC, Hamers RL, Noguera-Julian M, Casadell\u00e0 M, Parera M, Wit TFR et al. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa. J Antimicrob Chemother. 2018 May 1;73(5):1167-1172. PubMed | Google Scholar","DOI":"10.1093\/jac\/dky005"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Jacobson JM, Flexner CW. Universal antiretroviral regimens: thinking beyond one-pill-once-a-day. Curr Opin HIV AIDS. 2017 Jul;12(4):343-350. PubMed | Google Scholar","DOI":"10.1097\/COH.0000000000000374"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Thomford NE, Mhandire D, Dandara C, Kyei GB. Promoting U ndetectable Equals U ntransmittable in Sub-Saharan Africa: Implication for Clinical Practice and ART Adherence. Int J Environ Res Public Health. 2020 Aug 25;17(17):6163. PubMed | Google Scholar","DOI":"10.3390\/ijerph17176163"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Fofana DB, D\u00b4Almeida M, Lambert-Niclot S, Peytavin G, Girard PM, Lafia B et al. Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West Africa. J Antimicrob Chemother. 2018 Nov 1;73(11):3143-3147. PubMed | Google Scholar","DOI":"10.1093\/jac\/dky300"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Fokam J, Salpini R, Santoro MM, Cento V, Perno CF, Colizzi V et al. Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. Pediatr Infect Dis J. 2011 Dec;30(12):1062-8. PubMed | Google Scholar","DOI":"10.1097\/INF.0b013e31822db54c"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Rhee SY, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R et al. HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. PLoS One. 2015 Dec 30;10(12):e0145772. PubMed | Google Scholar","DOI":"10.1371\/journal.pone.0145772"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Takou D, Fokam J, Teto G, Santoro MM, Ceccherini-Silberstein F, Nanfack AJ et al. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon. BMC Infect Dis. 2019 Mar 12;19(1):246. PubMed | Google Scholar","DOI":"10.1186\/s12879-019-3871-0"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Tchouwa GF, Eymard-Duvernay S, Cournil A, Lamare N, Serrano L, Butel C et al. Nationwide Estimates of Viral Load Suppression and Acquired HIV Drug Resistance in Cameroon. EClinicalMedicine. 2018 Jul 4;1:21-27. PubMed | Google Scholar","DOI":"10.1016\/j.eclinm.2018.06.005"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Nicastri E, Sarmati L, d'Ettorre G, Parisi SG, Palmisano L, Galluzzo C et al. High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. J Clin Microbiol. 2003 Jul;41(7):3007-12. PubMed | Google Scholar","DOI":"10.1128\/JCM.41.7.3007-3012.2003"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Fokam J, Salpini R, Santoro MM, Cento V, D'Arrigo R, Gori C et al. Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. Arch Virol. 2011 Jul;156(7):1235-43. PubMed | Google Scholar","DOI":"10.1007\/s00705-011-0982-3"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Fokam J, Takou D, Teto G, Nforbih SE, Kome OP, Santoro MM et al. Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon. PLoS One. 2020 Jul 21;15(7):e0235958. PubMed | Google Scholar","DOI":"10.1371\/journal.pone.0235958"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Nyamache AK, Muigai AW, Nganga Z, Khamadi SA. HIV Type 1 genetic diversity and naturally occurring polymorphisms in HIV type 1 Kenyan isolates: implications for integrase inhibitors. AIDS Res Hum Retroviruses. 2012 Aug;28(8):933-6. PubMed | Google Scholar","DOI":"10.1089\/aid.2011.0122"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Vergne L, Bourgeois A, Mpoudi-Ngole E, Mougnutou R, Mbuagbaw J, Liegeois F et al. Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage. Virology. 2003 Jun 5;310(2):254-66. PubMed | Google Scholar","DOI":"10.1016\/S0042-6822(03)00167-3"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Villabona-Arenas CJ, Domyeum J, Mouacha F, Butel C, Delaporte E, Peeters M et al. HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges. Infect Genet Evol. 2015 Dec;36:210-216. PubMed | Google Scholar","DOI":"10.1016\/j.meegid.2015.09.006"}],"container-title":["Pan African Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T09:16:11Z","timestamp":1769591771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.panafrican-med-journal.com\/content\/article\/52\/122\/full\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":34,"URL":"https:\/\/doi.org\/10.11604\/pamj.2025.52.122.46773","relation":{},"ISSN":["1937-8688"],"issn-type":[{"value":"1937-8688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"article-number":"46773"}}